DE60215525D1 - Kombination aus quetiapin und zolmitriptan - Google Patents

Kombination aus quetiapin und zolmitriptan

Info

Publication number
DE60215525D1
DE60215525D1 DE60215525T DE60215525T DE60215525D1 DE 60215525 D1 DE60215525 D1 DE 60215525D1 DE 60215525 T DE60215525 T DE 60215525T DE 60215525 T DE60215525 T DE 60215525T DE 60215525 D1 DE60215525 D1 DE 60215525D1
Authority
DE
Germany
Prior art keywords
zolmitriptan
combination
quetiapin
sub
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60215525T
Other languages
English (en)
Other versions
DE60215525T2 (de
Inventor
David Lee
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Publication of DE60215525D1 publication Critical patent/DE60215525D1/de
Application granted granted Critical
Publication of DE60215525T2 publication Critical patent/DE60215525T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Hydrogenated Pyridines (AREA)
DE60215525T 2001-08-27 2002-08-23 Kombination aus quetiapin und zolmitriptan Expired - Lifetime DE60215525T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE0102855 2001-08-27
SE0102855A SE0102855D0 (sv) 2001-08-27 2001-08-27 Method of treatment
PCT/SE2002/001507 WO2003018009A1 (en) 2001-08-27 2002-08-23 A combination of quetiapine and zolmitriptan

Publications (2)

Publication Number Publication Date
DE60215525D1 true DE60215525D1 (de) 2006-11-30
DE60215525T2 DE60215525T2 (de) 2007-06-06

Family

ID=20285147

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60215525T Expired - Lifetime DE60215525T2 (de) 2001-08-27 2002-08-23 Kombination aus quetiapin und zolmitriptan

Country Status (12)

Country Link
US (2) US20050020571A1 (de)
EP (1) EP1423112B1 (de)
JP (1) JP2005503391A (de)
AT (1) ATE342720T1 (de)
AU (1) AU2002326271B2 (de)
CA (1) CA2456480A1 (de)
DE (1) DE60215525T2 (de)
ES (1) ES2274081T3 (de)
NZ (1) NZ530930A (de)
SE (1) SE0102855D0 (de)
WO (1) WO2003018009A1 (de)
ZA (1) ZA200401550B (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5823093B2 (ja) 2006-03-28 2015-11-25 ジャヴェリン ファーマシューティカルズ インコーポレイテッド 低投与量のジクロフェナク及びβ−シクロデキストリンの配合物
US7495024B2 (en) 2006-08-07 2009-02-24 Via Pharmaceuticals, Inc. Phenylalkyl N-hydroxyureas for combating atherosclerotic plaque
JP2012506404A (ja) * 2008-10-22 2012-03-15 ノバルティス アーゲー 片頭痛処置用組み合わせ剤
US20110091435A1 (en) * 2008-10-24 2011-04-21 University Of Southern California Phytoestrogenic formulations for alleviation or prevention of hair loss
US10457299B2 (en) * 2017-02-22 2019-10-29 Westinghouse Air Brake Technologies Corporation Train stop timer
US9993486B1 (en) 2017-06-19 2018-06-12 Tlc Therapeutics, Llc Oral quetiapine suspension formulations with extended shelf life and enhanced bioavailability

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8607684D0 (en) * 1986-03-27 1986-04-30 Ici America Inc Thiazepine compounds
CA2250042A1 (en) * 1996-03-25 1997-10-02 Eli Lilly And Company Treating pain using a synergistic combination of an atypical antipsychotic and a drug used in treatment of pain
US5948437A (en) * 1996-05-23 1999-09-07 Zeneca Limited Pharmaceutical compositions using thiazepine
GB9611328D0 (en) * 1996-05-31 1996-08-07 Zeneca Ltd Pharmaceutical compositions
US5872145A (en) * 1996-08-16 1999-02-16 Pozen, Inc. Formulation of 5-HT agonist and NSAID for treatment of migraine
GB9709815D0 (en) * 1997-05-14 1997-07-09 Merck Sharp & Dohme Therapeutic method
US6294192B1 (en) * 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
GB9922271D0 (en) * 1999-09-21 1999-11-17 Zeneca Ltd Formulation
GB9928578D0 (en) * 1999-12-03 2000-02-02 Zeneca Ltd Pharmaceutical formulations

Also Published As

Publication number Publication date
NZ530930A (en) 2006-01-27
EP1423112B1 (de) 2006-10-18
EP1423112A1 (de) 2004-06-02
US20080108596A1 (en) 2008-05-08
ES2274081T3 (es) 2007-05-16
US20050020571A1 (en) 2005-01-27
ATE342720T1 (de) 2006-11-15
JP2005503391A (ja) 2005-02-03
SE0102855D0 (sv) 2001-08-27
WO2003018009A1 (en) 2003-03-06
AU2002326271B2 (en) 2007-10-11
CA2456480A1 (en) 2003-03-06
ZA200401550B (en) 2004-11-17
DE60215525T2 (de) 2007-06-06

Similar Documents

Publication Publication Date Title
NO20050851L (no) Kaspase-inhibitorer og anvendelser derav
SE0104341D0 (sv) New use
ATE384058T1 (de) Thiazolderivate
TNSN07063A1 (fr) Utilisations therapeutiques d'inhibiteurs de rtp801
MX2007008614A (es) Peptidos con actividad agonista del receptor del neuropeptido-2 (y2r).
EP1841426A4 (de) Als inhibitoren von beta-secretase aktive tertiäre carbinamine mit substituierten heterocyclen zur behandlung der alzheimer-krankheit
CU23208A3 (es) Oxazolidinonas sustituidas y su uso en el campo de la coagulacion sanguinea
DE60209511D1 (de) Zusammensetzungen zur behandlung des schnupfens, welche ipratropium und xylometazolin enthalten
SG170101A1 (en) 2-pyrazinone derivatives for the treatment of disease or condition in which inhibition of neutrophil elastase activity is beneficial.
EE200400020A (et) Asendatud oksasolidinoonid kombineeritud raviks
UA92000C2 (en) 1-benzylindole-2-carboxamide derivatives
MXPA03011515A (es) Nuevas composiciones de medicamentos sobre la base de agentes anticolinergicos, corticoesteroides y agentes betamimeticos.
MXPA02012272A (es) Compuestos heterociclicos que son inhibidores de la enzima dipeptidilpeptidasa-iv.
EP1562897A4 (de) Phenylcarboxamide als beta-sekretase-hemmer zur behandlung von alzheimer
TW200616608A (en) Memantine as adjunctive treatment to atypical antipsychotics in schizophrenia patients
ATE301654T1 (de) Naphthyridinderivate
MXPA05008838A (es) Formulaciones de absorcion acelerada del agonista selectivo de la 5-ht.
DE602007011975D1 (de) Thiadiazolderivate zur behandlung neurodegenerativer krankheiten
HUP0203844A2 (hu) Növekedési hormon kibocsátó tulajdonságú vegyület, ezt tartalmazó gyógyszerkészítmény és alkalmazása
HUP0204520A2 (en) Pharmaceutical composition containing esmolol and process for its preparation
BR0201974A (pt) Composição farmacêutica para tratamento de alterações do sono
DE60215525D1 (de) Kombination aus quetiapin und zolmitriptan
ATE373644T1 (de) N-substituierte 3-hydroxy-4-pyridinone und diese enthaltende pharmazeutika
HUP0303910A2 (hu) Húgyhólyagbetegségek kezelésére szolgáló kappa-opiát agonisták alkalmazása gyógyszerkészítmények előállítására
SE0000303D0 (sv) Novel compounds

Legal Events

Date Code Title Description
8364 No opposition during term of opposition